Both SGLT2 inhibitors and GLP-1 receptor agonists showed lower odds of asthma compared with DPP-4 inhibitors and placebo, while SGLT2 inhibitors also demonstrated lower odds of COPD, respiratory failure, and bronchitis versus placebo. Here, SLC5A2 is linked to bronchitis.